


Booming Market: Neurological Biomarkers Projected to Hit \$18.9 Billion by 2031

WILMINGTON, DELAWARE, UNITED STATES, May 30, 2024 /EINPresswire.com/ -- Allied Market Research has recently unveiled a research study titled "Neurological Biomarkers Market Outlook and Forecast 2021-2031." This report delivers a comprehensive analysis of market risks, spotlights opportunities, and provides essential support for strategic and tactical decision-making spanning from 2021 to 2031. The study categorizes the market by pivotal



regions propelling its growth and commercialization. Moreover, the report encompasses vital insights into market research and development, growth catalysts, and the evolving investment landscape within Neurological Biomarkers.

Neurological biomarkers market size was valued at \$5.4 billion in 2021, and is estimated to reach \$18.9 billion by 2031, growing at a CAGR of 13.6% from 2022 to 2031. Ever-increasing rise in the incidence of Alzheimer's and Parkinson's is anticipated to contribute toward the robust growth of neurological biomarkers among these two applications. In addition, surge in adoption of neurological biomarkers in drug development and validation has increased over the years to improve the accuracy of clinical trials. Further, rise in transition toward personalized medicine is expected to offer profitable opportunities for the expansion of neurological biomarkers applied across Alzheimer's and Parkinson's.

The study provides an in-depth analysis of the neurological biomarkers market forecast, future estimations and neurological biomarkers market trends to elucidate the imminent investment pockets.

It presents a quantitative analysis of the market from 2021 to 2031 to enable stakeholders to capitalize on the prevailing neurological biomarkers market opportunity.

Extensive analysis of the market based on procedures and services assists to understand the trends in the neurological biomarkers industry.

Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the neurological biomarkers industry.

00000 0000 00 2031: USD 18.9 billion Growth Rate: CAGR of 13.6% Forecast period: 2021 - 2031 Genomic Proteomic Metabolomic Others Parkinson's Disease Alzheimer's Disease **Multiple Sclerosis** 00 000000: North America (U.S., Canada) Europe (Germany, France, UK, Rest Of Europe)

Asia-Pacific (Japan, China, India, Rest Of Asia-Pacific)
LAMEA (Brazil, Saudi Arabia, Rest Of LAMEA)
DDDD DD DDDDDDD : Bio-Rad Laboratories, Inc.
Quanterix
merck kgaa
darmstadt
germany
bioMérieux
F. HOFFMANN-LA ROCHE LTD.
MYRIAD RBM (MYRIAD GENETICS, INC.)
PERKINELMER INC.
Thermo Fisher Scientific, Inc.
Neurobio, shimadzu corporation
0000000 000000 000000 https://www.alliedmarketresearch.com/request-sample/3555
a. Genomic Biomarkers: This segment includes biomarkers derived from genes and their expression patterns, such as single nucleotide polymorphisms (SNPs) and gene expression profiles.

b. Proteomic Biomarkers: This segment includes biomarkers derived from proteins, such as

c. Imaging Biomarkers: This segment includes biomarkers obtained through various imaging

protein expression levels, protein modifications, and protein-protein interactions.

techniques, such as magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT) scans.

- d. Metabolomic Biomarkers: This segment includes biomarkers derived from metabolites, such as small molecules and metabolic pathways.
- e. Others: This segment may include other types of biomarkers, such as epigenetic biomarkers or microRNA biomarkers.

0000000 0000:

- a. Alzheimer's Disease: This segment focuses on biomarkers associated with Alzheimer's disease, such as amyloid beta and tau proteins.
- b. Parkinson's Disease: This segment focuses on biomarkers associated with Parkinson's disease, such as alpha-synuclein and dopamine levels.
- c. Multiple Sclerosis: This segment focuses on biomarkers associated with multiple sclerosis, such as myelin basic protein and neurofilament light chain.
- d. Stroke: This segment focuses on biomarkers associated with stroke, such as brain-derived neurotrophic factor (BDNF) and glial fibrillary acidic protein (GFAP).
- e. Other Neurological Disorders: This segment may include biomarkers associated with other neurological disorders, such as epilepsy, Huntington's disease, and traumatic brain injury.

000 0000:

- a. Hospitals and Clinics: This segment includes biomarker testing conducted in hospitals and clinics by healthcare professionals.
- b. Research Institutes and Academic Centers: This segment focuses on biomarker research conducted in academic and research settings.
- c. Diagnostic Laboratories: This segment includes biomarker testing conducted in specialized diagnostic laboratories.
- d. Pharmaceutical and Biotechnology Companies: This segment focuses on biomarker discovery and development carried out by pharmaceutical and biotech companies.

DDD: https://www.alliedmarketresearch.com/checkout-final/9f0e3bf3e66f160fbacb254909054633

- Which are the driving factors responsible for the growth of market?
- Which are the roadblock factors of this market?
- · What are the new opportunities, by which market will grow in coming years?
- · What are the trends of this market?
- Which are main factors responsible for new product launch?
- How big is the global & regional market in terms of revenue, sales and production?
- How far will the market grow in forecast period in terms of revenue, sales and production?

- Which region is dominating the global market and what are the market shares of each region in the overall market in 2023?
- How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
- Which region has more opportunities?

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

0000000 0000 0000000:

Neurological Biomarkers Market: https://www.alliedmarketresearch.com/neurological-biomarkers-market

Next Generation Diabetes Therapy and Drug Delivery Market:

https://www.alliedmarketresearch.com/next-generation-diabetes-therapy-and-drug-delivery-market

<u>Automated Liquid Handling Market:</u> https://www.alliedmarketresearch.com/automated-liquid-handling-market

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa

Portland, OR, United States

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022,

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1(855)550-5975

help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com

David Correa Allied Market Research + 18007925285 email us here Visit us on social media: Facebook

LinkedIn Other

This press release can be viewed online at: https://www.einpresswire.com/article/715861277

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.